Simultaneous measurement of two serum markers (CA-125 and HE-4) while diagnosing malignant ovarian epithelial tumors

Pakistan Journal of Medical Sciences

Volumn 27, Issue 4, 2011, Pages 858-861

  Modarres Gilani, Mitra ^a   Ghaemmaghami, Fatemeh ^a   Mousavi, Ashrafossadat ^a   Abbasi, Fatemeh ^a   Abdollahi, Alireza ^a   Shoar, Saeed ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CA 125; HE 4; Ovarian malignant epithelial tumors

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4;

ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; EPITHELIUM TUMOR; FEMALE; HUMAN; INTERMETHOD COMPARISON; IRAN; MAJOR CLINICAL STUDY; OVARY CANCER; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION;

EID: 80052983639     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Liu YN, Ye X, Cheng HY, Cheng YX, Fu TY, Chen J, et al. Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors. Zhonghua Fu Chan KeZaZhi 2010;45(5):363-366.
2. Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev 2010;11(1):111-116
3. Lamy PJ, Roques S, Viglianti C, Fabbro M, Montels F. HE4, a novel marker for epithelial ovarian cancer: Evaluation of analytical performances. Ann Biol Clin (Paris) 2010;68(3):325-329.
4. Anastasi E, Granato T, Marchei GG, Viggiani V, Colaprisca B, Comploj S, et al. Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumour Biol 2010;31(5):411-5. Epub 2010 May 20.
5. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010;203(3):228.e1-6. Epub 2010 May 14.
6. Hellstrom I, Heagerty PJ, Swisher EM, Liu P, Jaffar J, Agnew K, et al. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. Cancer Lett 2010;296(1):43-48. Epub 2010 Apr 8.
7. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010;28(13):2159-2166. Epub 2010 Apr 5.
8. Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: A new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 2010;31(2):113-119. Epub 2010 Jan 23.
9. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010;117(3):440-445. Epub 2010 Mar 24.
10. Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 2009;9(6):555-566. Review.
11. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64(16):5882-5890.
12. Montagnana M, Lippi G, Danese E, Franchi M, Guidi GC. Usefulness of serum HE4 in endometriotic cysts. Br J Cancer 2009;101(3):548. Epub 2009 Jun 9.
13. Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev 2009;18(5):1365-1372.
14. Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, et al. The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy. Zhonghua Fu Chan KeZaZhi 2008;43(12):931-936.
15. Lowe KA, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, et al. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008;17(9):2480-2487.
16. Bast RC Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003;21:200-205.
17. Hellstrom I, Raycroft J, Hayden-led better M, Ledbetter JA, Schummer M, MeIntosh M, et al. The HF4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Research 2003;63:3695-3700.
18. Bingle L, Singleton V, Bingle CD. The putative ovarian tumor marker gene HR4 (WFDC2) is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002;21:2768-2773.
19. Galgano M, Hampton G, Frierson HJ. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19:847-853.
20. Allard WJ, Moore RG. HE4 and CA125 combined for improved management ovarian cancer. Oncology 2009;3:20-21.